Posted by Michael Wonder on 01 Apr 2025
Pembrolizumab in combination with carboplatin and paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer
24 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of pembrolizumab in combination with carboplatin and paclitaxel in the NHS in England.
For the time being, pembrolizumab, when used in combination with carboplatin and paclitaxel, should not be used for the first-line treatment of adults with primary advanced or recurrent endometrial cancer.
